Brought to you by 
Shire gets rights to Alba's AT1001 for all indications; terminated
21 Mar 2016
Executive Summary
Alba Therapeutics licensed Shire PLC exclusive worldwide rights (except in the US and Japan) to develop and commercialize its AT1001 for all indications. The compound is currently in Phase II for celiac disease, a genetic disorder also known as gluten intolerance, for which there are currently no available therapeutic options.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Shire gets rights to Alba's AT1001 for all indications; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice